[A24-27] Nirsevimab (prevention of RSV disease) – Benefit assessment according to §35a Social Code Book V
Last updated 15.08.2024
Project no.:
A24-27
Commission:
Commission awarded on 04.03.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Children during their 1st RSV season with indication for secondary prophylaxis of lower respiratory tract infections caused by respiratory syncytial virus.
- Children in whom palivizumab is indicated: added benefit not proven
- Children in whom palivizumab is not indicated: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2024-07-18.
https://doi.org/10.60584/A24-27_en
| Project no. | Title | Status |
|---|---|---|
| A24-75 | Nirsevimab (secondary prophylaxis of RSV lower respiratory tract disease) - Addendum to Project A24-27 | Commission completed |
| A24-82 | Nirsevimab (secondary prophylaxis of RSV lower respiratory tract disease, 2nd. RSV season) – Benefit assessment according to §35a Social Code Book (SGB) V | Commission completed |
Federal Joint Committee (G-BA)
2024-08-15 A G-BA decision was published.